2020-2027 Analysis and Review Glaucoma Drugs Market

Glaucoma Drugs Market

Glaucoma Drugs Market By Drug Class (Prostaglandins, Beta Blockers, Alpha-Adrenergic Agonists, Carbonic anhydrase inhibitors and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

10-04-2020 REP-HC-5063 40 Tables 121 pages Format

The glaucoma drugs market was valued at USD2,808.2Mn by 2019. According to the latest statistics provided by the International Agency for the Prevention of Blindness (IAPB), by 2020 it is estimated that 80 million people will be suffering from glaucoma. The recent launch of novel drugs such as Rhopressa and Vyzulta will further accentuate the glaucoma market growth.

 Glaucoma Drugs Market

The most common types of glaucoma are open-angle glaucoma and angle-closure glaucoma, the chief attributes associated with the disease progression are visual field loss, optic nerve damage, retinal ganglion cell damage, etc. As per the statistics provided by the World Health Organization (WHO), glaucoma is responsible for blindness in 5.2 million people which represents 15% of world blindness.

The major segments related to the glaucoma drugs market are:

By Drug Class (2017–2027; US$ Mn)

Prostaglandins

Beta-Blockers

Alpha-Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global glaucoma drugs market
  • The overall segmentation of the glaucoma drugs market, by drug class, distribution channel, and geography is minutely studied. Prostaglandins and hospital pharmacy are dominating the drug class and distribution channel segments respectively
  • Significant increase in glaucoma ophthalmic disorder worldwide determines the glaucoma drugs market growth
  • Recent launch of novel therapeutics in glaucoma management such as Rhopressa and Vyzulta will further accentuate the market growth

Report gist?

  • The study of the global glaucoma drugs market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of drug class and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing of glaucoma drugs on account of the rising prevalence of glaucoma worldwide
  • The report will benefit researchers engaged in the novel drug development for the management of glaucoma
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to glaucoma drugs market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Prostaglandins are dominating the drug class segment for the glaucoma drugs market. They exhibit excellent patient compliance as only a single dose is required daily, it exerts its therapeutic effect by relaxing muscles of the eye's interior structure in order to promote fluid drainage and reduce eye pressure. Beta-blockers are used in combination with prostaglandins for the treatment of glaucoma, it exhibits its pharmacological effect by reducing the fluid production in the eye. Carbonic anhydrase inhibitors and alpha-adrenergic agonists are used in combination with other drugs and are critical in decreasing the rate of aqueous humor production in order to treat glaucoma. Another segment comprises novel drugs that are being employed in glaucoma management such as Rhopressa and Vyzulta which have superior therapeutic efficacy and safety in comparison to traditional drugs.

Hospital pharmacy is reigning the distribution channel segment for the glaucoma drug market. The majority of the drug class employed for the treatment of glaucoma is associated with side effects and hence it becomes imperative for precise compounding of glaucoma drugs by the hospital pharmacist as per the physician’s prescription. Retail pharmacy is estimated to register rampant market growth in the near future owing to its ability to provide generic versions of glaucoma drugs at attractive prices.

In the present scenario North America is clearly leading the geography segment for the glaucoma drugs market. The rising prevalence of glaucoma primarily drives the glaucoma drug market in the region. According to the recent research findings presented by BrightFocus Foundation approximately 3 million Americans are suffering from glaucoma and only half of them know about it. Additionally, the presence of well-developed healthcare infrastructure and domicile of key players such as Allergan, Plc., Alcon, Bausch & Lomb, Novartis AG, etc. further accentuate the market growth in the region. Europe is considered as the second-largest regional market due to the affordable reimbursement scenario for glaucoma drugs and supportive regulatory environment provided by the European Medical Agency (EMA) for the sale and distribution of glaucoma drugs in the region. Asia Pacific is set to be the fastest-growing regional market for glaucoma drugs chiefly due to the rising prevalence of glaucoma in the elderly population and the presence of flourishing generic drugs market.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.